A Tumor-Localized Approach to Bypass Anti-4-1BB Immuno-Toxicity.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31366600.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1799.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
4-1BB (CD137) is an important costimulatory molecule upregulated on antigen-experienced T cells, however, clinical development of 4-1BB agonists has stalled because of significant liver immuno-toxicity. Using rational protein engineering, a next-generation anticalin-antibody-based therapy achieved localized 4-1BB activation triggered by tumor-expressed antigen, helping to revitalize this pathway in immuno-oncology.<i>See related article by Hinner et al., p. 5878</i>.
Medical subject headings
- Neoplasms
- Tumor Necrosis Factor Receptor Superfamily, Member 9